Back to Top Skip to main content

DOD participates in new COVID-19 antibody combination prevention trial

Woman gets blood drawn Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

WWII soldier and his wife receive COVID-19 vaccine

Article
3/5/2021
Military personnel wearing a mask, giving the COVID-19 vaccine to a veteran wearing a mask

Beck’s arrival signals a new phase of Fort Carson’s COVID-19 vaccination efforts for TRICARE beneficiaries 75 and older.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

Is It Your Time to Get the COVID-19 Vaccine?

Infographic
3/5/2021
This graphic informs TRICARE beneficiaries which tier they fall into as their local military treatment facility or clinic offers the vaccine.

This Infographic informs TRICARE beneficiaries which tier they fall into as their local military treatment facility or clinic offers the vaccine.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

DoD COVID-19 Practice Management Guide Version 7

Technical Document
3/4/2021

This Practice Management Guide does not supersede DoD Policy. It is based upon the best information available at the time of publication. It is designed to provide information and assist decision making. It is not intended to define a standard of care and should not be construed as one. Neither should it be interpreted as prescribing an exclusive course of management. It was developed by experts in this field. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of this guideline is responsible for evaluating the appropriateness of applying it in the setting of any particular clinical situation. The Practice Management Guide is not intended to represent TRICARE policy. Further, inclusion of recommendations for specific testing and/or therapeutic interventions within this guide does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor.

Recommended Content:

Coronavirus

Army Recruiter volunteers to administer COVID-19 vaccination

Article
3/2/2021
Military health personnel wearing a face mask giving someone the COVID-19 Vaccine

Army Master Sgt. Carolyn Lange has kept up her skills as a licensed practical nurse by administering COVID-19 vaccines on Fort George G. Meade in Maryland

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit | COVID-19 Toolkit

COVID-19: DOD vaccinates more than 1 million beneficiaries worldwide

Article
3/1/2021
Military personnel wearing face mask standing in line to receive their COVID-19 Vaccine

As DOD surpasses the administration of 1 million COVID-19 vaccine shots in arms, leaders reflect on how each military treatment facility community made the success possible, despite challenges.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit | COVID-19 Toolkit

DOD officials provide COVID-19 response update

Article
3/1/2021
Military personnel wearing a face mask handling prescription refills at a pharmacy

DoD officials present update on COVID-19 response efforts

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit | COVID-19 Toolkit | COVID-19 Vaccine Efforts

Cardiovascular providers counter pandemic-induced sedentary lifestyle

Article
2/26/2021
Military health personnel sticking an IV in a patient's arm

COVID-19 fears likely affecting cardiovascular care but not at military medical treatment facilities.

Recommended Content:

Coronavirus | Heart Health | Medical and Dental Preventive Care Fitness | February Toolkit | Preventing Heart Disease

Secretary of Defense Video to the Force on COVID-19 Vaccinations

Video
2/24/2021
Image of soldier looking through COVID vaccine information laid out on a table

The Secretary of Defense addressed the entire workforce to encourage informed decision-making with regards to coronavirus-19 vaccination.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Trained military personnel ready to help with COVID-19 vaccinations

Article
2/23/2021
Military health personnel wearing a mask giving the COVID-19 vaccine to a man who is also wearing a face mask

Military prepped and ready to help with civilian COVID-19 mass vaccinations

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | Immunizations

Marines, Sailors with PHIBRON 11, 31st MEU receive COVID-19 vaccine

Article
2/19/2021
Military health personnel giving the COVID-19 Vaccine to military personnel

Vaccination for service members is voluntary, as vaccines are currently authorized for emergency use.

Recommended Content:

Coronavirus | Immunization Healthcare | COVID-19 Vaccine Efforts

USU cohort study investigates COVID-19 impacts on DOD personnel

Article
2/18/2021
Military health personnel wearing a mask and a face shield holding up a sign that has the number eighteen on it

USU is conducting a study to better understand the symptoms and course of COVID-19 disease and identify risk factors in the military population.

Recommended Content:

COVID-19 Toolkit | Immunizations | COVID-19 Vaccine Efforts | Coronavirus

COVID-19, Influenza provide twice the challenge to healthcare workers

Article
2/17/2021
Military personnel wearing a face mask while holding hand sanitizer

The ongoing pandemic outbreak has overlapped with the annual Northern Hemisphere influenza season.

Recommended Content:

Influenza Vaccine Availability | Coronavirus | COVID-19 Vaccine Efforts

COVID-19 vaccine does not affect fertility, immunization experts say

Article
2/16/2021
Black and white photo of a couple holding hands

COVID-19 vaccination when pregnant or breastfeeding shows no harm, immunologists weigh in.

Recommended Content:

Women's Health | Coronavirus | COVID-19 Vaccine Efforts

DHA IT helps beneficiaries, providers and workforce through pandemic

Article
2/12/2021
Several military personnel, wearing masks, filling out paperwork. One woman is giving the thumbs up sign

DHA IT Teams Deliver Innovative Solutions During Pandemic.

Recommended Content:

Technology | Coronavirus

Printable VAX Fact Should Children Get the COVID Vaccine?

Publication
2/12/2021

This is a printable version of the VAX Fact graphic

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit | COVID-19 Vax Facts
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 27

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.